CN114929223A - 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 - Google Patents

用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 Download PDF

Info

Publication number
CN114929223A
CN114929223A CN202080087596.7A CN202080087596A CN114929223A CN 114929223 A CN114929223 A CN 114929223A CN 202080087596 A CN202080087596 A CN 202080087596A CN 114929223 A CN114929223 A CN 114929223A
Authority
CN
China
Prior art keywords
group
optionally substituted
alkyl
methyl
aromatic heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080087596.7A
Other languages
English (en)
Chinese (zh)
Inventor
杰米·L·哈登
汉斯·E·J·霍夫兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Priority to CN202410650258.XA priority Critical patent/CN118806758A/zh
Publication of CN114929223A publication Critical patent/CN114929223A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN202080087596.7A 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物 Pending CN114929223A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410650258.XA CN118806758A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962931132P 2019-11-05 2019-11-05
US62/931,132 2019-11-05
US202063046143P 2020-06-30 2020-06-30
US63/046,143 2020-06-30
PCT/US2020/059200 WO2021092239A1 (en) 2019-11-05 2020-11-05 Topical compositions comprising irak4 inhibitors for use in treating dermatological conditions characterised by inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410650258.XA Division CN118806758A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Publications (1)

Publication Number Publication Date
CN114929223A true CN114929223A (zh) 2022-08-19

Family

ID=73654894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080087596.7A Pending CN114929223A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物
CN202410650258.XA Pending CN118806758A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410650258.XA Pending CN118806758A (zh) 2019-11-05 2020-11-05 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物

Country Status (9)

Country Link
US (1) US20230125380A1 (https=)
EP (1) EP4054573A1 (https=)
JP (1) JP2023500707A (https=)
CN (2) CN114929223A (https=)
AU (1) AU2020380921A1 (https=)
BR (1) BR112022008610A2 (https=)
CA (1) CA3159624A1 (https=)
IL (1) IL292689A (https=)
WO (1) WO2021092239A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116134038A (zh) * 2020-06-30 2023-05-16 德米拉公司 Irak4抑制剂及其局部用途
CN116675780A (zh) * 2023-06-02 2023-09-01 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899505A (zh) * 2013-11-08 2016-08-24 武田药品工业株式会社 用于治疗自身免疫病症的吡唑
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
CN108026065A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
US20190192688A1 (en) * 2017-12-20 2019-06-27 Translate Bio, Inc. Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2021300110A1 (en) * 2020-06-30 2023-02-02 Dermira, Inc. IRAK4 inhibitors and topical uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899505A (zh) * 2013-11-08 2016-08-24 武田药品工业株式会社 用于治疗自身免疫病症的吡唑
CN108026065A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US20190192688A1 (en) * 2017-12-20 2019-06-27 Translate Bio, Inc. Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116134038A (zh) * 2020-06-30 2023-05-16 德米拉公司 Irak4抑制剂及其局部用途
CN116675780A (zh) * 2023-06-02 2023-09-01 东北农业大学 犬成纤维细胞生长因子21融合蛋白制备及其在治疗特应性皮炎中的用途

Also Published As

Publication number Publication date
WO2021092239A1 (en) 2021-05-14
IL292689A (en) 2022-07-01
US20230125380A1 (en) 2023-04-27
BR112022008610A2 (pt) 2022-08-09
EP4054573A1 (en) 2022-09-14
JP2023500707A (ja) 2023-01-10
CA3159624A1 (en) 2021-05-14
AU2020380921A1 (en) 2022-05-26
CN118806758A (zh) 2024-10-22

Similar Documents

Publication Publication Date Title
Noji et al. Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (delgocitinib) as a new dermatological agent to treat inflammatory skin disorders
KR101332585B1 (ko) 이미다조［１，２―ａ］피라진 유도체와, 신경계, 정신과 및 대사 장애 및 질환을 예방 또는 치료하기 위한 그의 용도
TWI731317B (zh) 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
HK1252318A1 (zh) 抗菌治疗剂和预防剂
KR20120102667A (ko) 이미다조［１，２?ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
US20260078103A1 (en) Isoquinolones as pi3k inhibitors
RU2667058C2 (ru) Ингибиторы фермента фосфодиэстеразы 10
CN114929223A (zh) 用于治疗以炎症为特征的皮肤病状的包括irak4抑制剂的局部组合物
TW201808944A (zh) 神經病症的治療
JP7593956B2 (ja) Ｒｈｏキナーゼ阻害薬及び組成物並びにそれらの使用の方法
ES2825498T3 (es) Composiciones sinérgicas que comprenden (R)-dimiracetam (1) y (S)-dimiracetam (2) en una proporción no racémica
JP7813733B2 (ja) Ｉｒａｋ４阻害剤及びそれらの局所的使用方法
EP3148518B1 (en) Novel compounds as anti-tubercular agents
CN103827100B (zh) 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物
CN114929335A (zh) RORγt抑制剂及其局部用途
WO2020063659A1 (en) Substituted [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
CN113164487B (zh) 磷酸二酯酶抑制剂
KR20250157396A (ko) 하이드록시알킬 및 메톡시알킬 트립타민
Micheli et al. Synthesis and Anti‐Hyperalgesic Efficacy of MP‐103, a Non‐Racemic Enantiomeric Mixture of a New 1, 4‐Diazabicyclo [4.3. 0] nonan‐9‐one
WO2025101588A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
WO2015162076A2 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities
HK1227395A1 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220819